News

Before joining Auron Therapeutics, Roman worked at Schrödinger as a Director of Pharmaceutical Sciences, where he served as Pharmaceutics and Drug Product lead on multiple Development and Discovery programs, directly contributing to two IND filings for novel cancer therapeutics. Prior to Schrodinger, Roman was a Senior Principal Scientist at Celgene, which was later acquired by BMS, where he established…

Chris is our President & Chief Operating Officer. Before joining Auron, he served as Chief Financial Officer & Chief Operating Officer of Pear Therapeutics, Inc. Before that, he served as President & Chief Executive Officer of Cerulean Pharma. He previously served as Cerulean’s Chief Operating Officer and before that as its Senior Vice President and…

Mark joins Auron Therapeutics with diverse discovery and translational oncology experience from a number of organizations including Merck, Agios, Dana Farber’s Belfer Center, and most recently, Parthenon Therapeutics.   Throughout his industry career, Mark has worked on developing cancer therapies targeting multiple metabolic, epigenetic, and signaling proteins, with his most recent work aimed at targeting the…

Jake is a medicinal chemist with 20 years experience in the industry. Prior to joining Auron he worked at Novartis Institutes for BioMedical Research. He started his career in 2003 at the Horsham UK site as an apprentice, acquiring his BSc in Chemistry from the university of Greenwich via a part time course while working….

Colleen DeSimone has more than 25 years of strategic financial and operational experience in the biotechnology and pharmaceutical industries. Most recently, she provided financial consulting services for Casma since its inception and for numerous early-stage biotechnology companies. Previously, Colleen served as vice president of finance and controller at Syros Pharmaceuticals. Colleen joined Syros from Takeda…

Sambad comes to us most recently from Nirogy Therapeutics where he led the biology team to execute IND enabling studies of Nirogy’s lead small molecule inhibitor. He also led studies that identified mechanism of action of Nirogy’s metabolic inhibitor in direct cancer cell killing and activation of antitumor immunity. Before joining Nirogy, Sambad did his…

Christina received her Bachelor’s degree from University of Massachusetts/Amherst in Microbiology. She has been in and out of small biotech companies for over a decade and a half. Most recently, she spent a little over a year at Faze Medicines, where she worked on the impact of condensates in an oncology setting. Before that, she…

Tori joined Auron Therapeutics in August, 2022. Prior to joining Auron “officially” she worked as an HR Benefits Consultant for Auron and Celsius Therapeutics. Tori has an extensive background of working with early stage biotechnology companies to support the development of their operations, Human Resources and administration. She has held positions at Agios Pharmaceutics and…